Immuneering Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:IMRX Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
16 Jan 26	BuyUS$24,990	Harold Brakewood	Individual	5,250	US$4.76
15 Jan 26	BuyUS$10,502	Brett Hall	Individual	2,298	US$4.57
15 Jan 26	BuyUS$101,041	Thomas Schall	Individual	21,645	US$4.67
13 Jan 26	BuyUS$10,906	Leah Neufeld	Individual	2,626	US$4.15
12 Jan 26	BuyUS$86,904	Peter Feinberg	Individual	20,000	US$4.35
03 Oct 25	BuyUS$50,025	Peter Feinberg	Individual	7,500	US$6.67
01 Oct 25	BuyUS$6,966	Michael Bookman	Individual	1,020	US$6.83
01 Oct 25	BuyUS$5,103	Leah Neufeld	Individual	800	US$6.38
01 Oct 25	BuyUS$1,917	Mallory Morales	Individual	300	US$6.39
30 Sep 25	BuyUS$52,730	Peter Feinberg	Individual	7,500	US$7.03
29 Sep 25	BuyUS$35,900	Peter Feinberg	Individual	5,000	US$7.18
02 Jul 25	BuyUS$34,879	Benjamin Zeskind	Individual	10,000	US$3.53
02 Jul 25	BuyUS$2,499	Leah Neufeld	Individual	700	US$3.57
02 Jul 25	BuyUS$19,863	Diana Hausman	Individual	5,500	US$3.62
27 Jun 25	BuyUS$34,788	Thomas Schall	Individual	9,500	US$3.66
23 Jun 25	BuyUS$34,616	Brett Hall	Individual	13,422	US$2.70
20 Jun 25	BuyUS$4,804	Harold Brakewood	Individual	1,900	US$2.53
18 Jun 25	BuyUS$50,144	Benjamin Zeskind	Individual	21,000	US$2.39
18 Jun 25	BuyUS$63,188	Peter Feinberg	Individual	25,000	US$2.53
17 Jun 25	BuyUS$89,278	Thomas Schall	Individual	40,485	US$2.21

Insider Trading Volume

Insider Buying: IMRX insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of IMRX?
Owner Type	Number of Shares	Ownership Percentage
Public Companies	2,708,559	4.19%
Private Companies	3,646,304	5.65%
Individual Insiders	8,895,482	13.8%
General Public	20,178,586	31.3%
Institutions	29,141,036	45.1%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 108%.

Top Shareholders

Top 25 shareholders own 62.81% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
15%	FMR LLC	9,685,495	US$48.0m	10.2%	no data
5.65%	Hbm Healthcare Investments (Cayman) Ltd.	3,646,304	US$18.1m	0%	no data
4.97%	Benjamin Zeskind	3,207,779	US$15.9m	0%	no data
4.29%	Seth Merrin	2,770,386	US$13.7m	0%	no data
4.19%	Sanofi	2,708,559	US$13.4m	0%	0.78%
4.14%	Empery Asset Management, LP	2,674,950	US$13.3m	-34.9%	13.28%
3.98%	The Vanguard Group, Inc.	2,568,293	US$12.7m	6.34%	no data
3.72%	State Street Global Advisors, Inc.	2,402,238	US$11.9m	1,290%	no data
3.09%	T. Rowe Price Group, Inc.	1,993,958	US$9.9m	10.9%	no data
2.25%	BlackRock, Inc.	1,451,706	US$7.2m	113%	no data
1.8%	Peter Feinberg	1,161,064	US$5.8m	1.75%	no data
1.78%	Robert Carpenter	1,148,839	US$5.7m	0%	no data
1.1%	Marshall Wace LLP	711,875	US$3.5m	162%	no data
1.03%	CHI Advisors LLC	665,000	US$3.3m	20.9%	1.64%
0.96%	Geode Capital Management, LLC	618,074	US$3.1m	20.3%	no data
0.77%	Occam Crest Management LP	498,498	US$2.5m	0%	1.62%
0.76%	Morgan Stanley	489,375	US$2.4m	66%	no data
0.58%	Brett Hall	376,496	US$1.9m	0.61%	no data
0.49%	The Goldman Sachs Group, Inc.	318,809	US$1.6m	0%	no data
0.46%	Burkehill Global Management, LP	300,000	US$1.5m	0%	0.1%
0.43%	Southport Management, L.L.C.	277,501	US$1.4m	1.83%	4.21%
0.38%	Diametric Capital, LP	246,857	US$1.2m	-2.12%	0.31%
0.33%	Dcf Advisers, Llc	215,000	US$1.1m	46.3%	0.32%
0.33%	Bank of America Corporation	214,341	US$1.1m	392%	no data
0.32%	Two Sigma Investments, LP	207,155	US$1.0m	92%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/02/24 19:58
End of Day Share Price	2026/02/24 00:00
Earnings	2025/09/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Immuneering Corporation is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Yevgeniya Livshits	Chardan Capital Markets, LLC
Michael Yee	Jefferies LLC
Andrew Berens	Leerink Partners LLC